Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C24H28N2O5 |
Molecular Weight | 424.4895 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 2 / 2 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@H]2CCC3=C(C=CC=C3)N(CC(O)=O)C2=O
InChI
InChIKey=XPCFTKFZXHTYIP-PMACEKPBSA-N
InChI=1S/C24H28N2O5/c1-2-31-24(30)20(14-12-17-8-4-3-5-9-17)25-19-15-13-18-10-6-7-11-21(18)26(23(19)29)16-22(27)28/h3-11,19-20,25H,2,12-16H2,1H3,(H,27,28)/t19-,20-/m0/s1
Molecular Formula | C24H28N2O5 |
Molecular Weight | 424.4895 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 2 / 2 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
DescriptionCurator's Comment: description was created based on several sources, including:
https://www.drugs.com/pro/benazepril.html | DOI: 10.1111/j.1527-3466.1990.tb00432.x
Curator's Comment: description was created based on several sources, including:
https://www.drugs.com/pro/benazepril.html | DOI: 10.1111/j.1527-3466.1990.tb00432.x
Benazepril is a prodrug which is metabolized by the liver into its active form benazeprilat via cleavage of the drug's ester group. Benazepril and Benazeprilat inhibit angiotensin-converting enzyme (ACE) in human subjects and animals. Benazeprilat has much greater ACE inhibitory activity than does Benazepril. It is indicated for the treatment of hypertension. It may be used alone or in combination with thiazide diuretics. Adverse reactions reported in controlled clinical trials and rarer events seen in post-marketing experience, include the following: Stevens-Johnson syndrome, pemphigus, apparent hypersensitivity reactions (manifested by dermatitis, pruritus, or rash), photosensitivity, and flushing, nausea, pancreatitis, constipation, gastritis, vomiting, and melena, thrombocytopenia and hemolytic anemia, anxiety, decreased libido, hypertonia, insomnia, nervousness, and paresthesia. Patients on diuretics, especially those in whom diuretic therapy was recently instituted, may occasionally experience an excessive reduction of blood pressure after initiation of therapy with Benazepril. Increased serum lithium levels and symptoms of lithium toxicity have been reported in patients receiving ACE inhibitors (including benazepril) during therapy with lithium.
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL1808 |
14.0 nM [IC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | LOTENSIN Approved UseAmlodipine besylate and benazepril hydrochloride capsules is a combination capsule of amlodipine, a dihydropyridine calcium channel blocker (DHP CCB) and benazepril, an angiotensin converting enzyme (ACE) inhibitor. Amlodipine besylate and benazepril hydrochloride capsules are indicated for the treatment of hypertension in patients not adequately controlled on monotherapy with either agent (1) 1.1 Hypertension Amlodipine besylate and benazepril hydrochloride capsules are indicated for the treatment of hypertension in patients not adequately controlled on monotherapy with either agent. Launch Date6.7780798E11 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
437 pmol/g EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/2344861 |
10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered: |
BENAZEPRIL plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
334 pmol × h/g EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/2344861 |
10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered: |
BENAZEPRIL plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
0.6 h EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/2344861 |
10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered: |
BENAZEPRIL plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
Doses
Dose | Population | Adverse events |
---|---|---|
10 mg 1 times / day multiple, oral Recommended Dose: 10 mg, 1 times / day Route: oral Route: multiple Dose: 10 mg, 1 times / day Sources: |
unhealthy, adult n = 116 Health Status: unhealthy Condition: Essential hypertension Age Group: adult Population Size: 116 Sources: |
Other AEs: Headache, Back pain... Other AEs: Headache (8.6%) Sources: Back pain (2.6%) Diarrhoea (0.9%) Upper respiratory tract infection (3.4%) Peripheral oedema (1.7%) Sinusitis (1.7%) Fatigue (0.9%) Cough (1.7%) Arthralgia (0.9%) |
10 mg 1 times / day multiple, oral Recommended Dose: 10 mg, 1 times / day Route: oral Route: multiple Dose: 10 mg, 1 times / day Sources: |
unhealthy n = 193 Health Status: unhealthy Condition: Essential hypertension Population Size: 193 Sources: |
Other AEs: Headache, Fatigue... Other AEs: Headache (9%) Sources: Fatigue (2%) Nausea (2%) Dizziness (2%) Cough increased (2%) |
20 mg 1 times / day multiple, oral Recommended Dose: 20 mg, 1 times / day Route: oral Route: multiple Dose: 20 mg, 1 times / day Sources: |
unhealthy n = 1145 Health Status: unhealthy Condition: Essential hypertension Population Size: 1145 Sources: |
Other AEs: Headache, Fatigue... Other AEs: Headache (3%) Sources: Fatigue (2%) Nausea (1%) Dizziness (3%) Dizziness postural (1%) Cough increased (2%) |
40 mg 1 times / day multiple, oral Recommended Dose: 40 mg, 1 times / day Route: oral Route: multiple Dose: 40 mg, 1 times / day Sources: |
unhealthy n = 771 Health Status: unhealthy Condition: Essential hypertension Population Size: 771 Sources: |
Other AEs: Headache, Fatigue... Other AEs: Headache (3%) Sources: Fatigue (2%) Nausea (1%) Dizziness (2%) Dizziness postural (1%) Cough increased (1%) |
5 mg 1 times / day multiple, oral (max) Recommended Dose: 5 mg, 1 times / day Route: oral Route: multiple Dose: 5 mg, 1 times / day Sources: |
unhealthy n = 184 Health Status: unhealthy Condition: Essential hypertension Population Size: 184 Sources: |
Other AEs: Headache, Dizziness... Other AEs: Headache (6%) Sources: Dizziness (2%) Dizziness postural (2%) |
80 mg 1 times / day multiple, oral Recommended Dose: 80 mg, 1 times / day Route: oral Route: multiple Dose: 80 mg, 1 times / day Sources: |
unhealthy n = 86 Health Status: unhealthy Condition: Essential hypertension Population Size: 86 Sources: |
Other AEs: Headache, Fatigue... Other AEs: Headache (2%) Sources: Fatigue (5%) Nausea (1%) Cough increased (1%) |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Arthralgia | 0.9% | 10 mg 1 times / day multiple, oral Recommended Dose: 10 mg, 1 times / day Route: oral Route: multiple Dose: 10 mg, 1 times / day Sources: |
unhealthy, adult n = 116 Health Status: unhealthy Condition: Essential hypertension Age Group: adult Population Size: 116 Sources: |
Diarrhoea | 0.9% | 10 mg 1 times / day multiple, oral Recommended Dose: 10 mg, 1 times / day Route: oral Route: multiple Dose: 10 mg, 1 times / day Sources: |
unhealthy, adult n = 116 Health Status: unhealthy Condition: Essential hypertension Age Group: adult Population Size: 116 Sources: |
Fatigue | 0.9% | 10 mg 1 times / day multiple, oral Recommended Dose: 10 mg, 1 times / day Route: oral Route: multiple Dose: 10 mg, 1 times / day Sources: |
unhealthy, adult n = 116 Health Status: unhealthy Condition: Essential hypertension Age Group: adult Population Size: 116 Sources: |
Cough | 1.7% | 10 mg 1 times / day multiple, oral Recommended Dose: 10 mg, 1 times / day Route: oral Route: multiple Dose: 10 mg, 1 times / day Sources: |
unhealthy, adult n = 116 Health Status: unhealthy Condition: Essential hypertension Age Group: adult Population Size: 116 Sources: |
Peripheral oedema | 1.7% | 10 mg 1 times / day multiple, oral Recommended Dose: 10 mg, 1 times / day Route: oral Route: multiple Dose: 10 mg, 1 times / day Sources: |
unhealthy, adult n = 116 Health Status: unhealthy Condition: Essential hypertension Age Group: adult Population Size: 116 Sources: |
Sinusitis | 1.7% | 10 mg 1 times / day multiple, oral Recommended Dose: 10 mg, 1 times / day Route: oral Route: multiple Dose: 10 mg, 1 times / day Sources: |
unhealthy, adult n = 116 Health Status: unhealthy Condition: Essential hypertension Age Group: adult Population Size: 116 Sources: |
Back pain | 2.6% | 10 mg 1 times / day multiple, oral Recommended Dose: 10 mg, 1 times / day Route: oral Route: multiple Dose: 10 mg, 1 times / day Sources: |
unhealthy, adult n = 116 Health Status: unhealthy Condition: Essential hypertension Age Group: adult Population Size: 116 Sources: |
Upper respiratory tract infection | 3.4% | 10 mg 1 times / day multiple, oral Recommended Dose: 10 mg, 1 times / day Route: oral Route: multiple Dose: 10 mg, 1 times / day Sources: |
unhealthy, adult n = 116 Health Status: unhealthy Condition: Essential hypertension Age Group: adult Population Size: 116 Sources: |
Headache | 8.6% | 10 mg 1 times / day multiple, oral Recommended Dose: 10 mg, 1 times / day Route: oral Route: multiple Dose: 10 mg, 1 times / day Sources: |
unhealthy, adult n = 116 Health Status: unhealthy Condition: Essential hypertension Age Group: adult Population Size: 116 Sources: |
Cough increased | 2% | 10 mg 1 times / day multiple, oral Recommended Dose: 10 mg, 1 times / day Route: oral Route: multiple Dose: 10 mg, 1 times / day Sources: |
unhealthy n = 193 Health Status: unhealthy Condition: Essential hypertension Population Size: 193 Sources: |
Dizziness | 2% | 10 mg 1 times / day multiple, oral Recommended Dose: 10 mg, 1 times / day Route: oral Route: multiple Dose: 10 mg, 1 times / day Sources: |
unhealthy n = 193 Health Status: unhealthy Condition: Essential hypertension Population Size: 193 Sources: |
Fatigue | 2% | 10 mg 1 times / day multiple, oral Recommended Dose: 10 mg, 1 times / day Route: oral Route: multiple Dose: 10 mg, 1 times / day Sources: |
unhealthy n = 193 Health Status: unhealthy Condition: Essential hypertension Population Size: 193 Sources: |
Nausea | 2% | 10 mg 1 times / day multiple, oral Recommended Dose: 10 mg, 1 times / day Route: oral Route: multiple Dose: 10 mg, 1 times / day Sources: |
unhealthy n = 193 Health Status: unhealthy Condition: Essential hypertension Population Size: 193 Sources: |
Headache | 9% | 10 mg 1 times / day multiple, oral Recommended Dose: 10 mg, 1 times / day Route: oral Route: multiple Dose: 10 mg, 1 times / day Sources: |
unhealthy n = 193 Health Status: unhealthy Condition: Essential hypertension Population Size: 193 Sources: |
Dizziness postural | 1% | 20 mg 1 times / day multiple, oral Recommended Dose: 20 mg, 1 times / day Route: oral Route: multiple Dose: 20 mg, 1 times / day Sources: |
unhealthy n = 1145 Health Status: unhealthy Condition: Essential hypertension Population Size: 1145 Sources: |
Nausea | 1% | 20 mg 1 times / day multiple, oral Recommended Dose: 20 mg, 1 times / day Route: oral Route: multiple Dose: 20 mg, 1 times / day Sources: |
unhealthy n = 1145 Health Status: unhealthy Condition: Essential hypertension Population Size: 1145 Sources: |
Cough increased | 2% | 20 mg 1 times / day multiple, oral Recommended Dose: 20 mg, 1 times / day Route: oral Route: multiple Dose: 20 mg, 1 times / day Sources: |
unhealthy n = 1145 Health Status: unhealthy Condition: Essential hypertension Population Size: 1145 Sources: |
Fatigue | 2% | 20 mg 1 times / day multiple, oral Recommended Dose: 20 mg, 1 times / day Route: oral Route: multiple Dose: 20 mg, 1 times / day Sources: |
unhealthy n = 1145 Health Status: unhealthy Condition: Essential hypertension Population Size: 1145 Sources: |
Dizziness | 3% | 20 mg 1 times / day multiple, oral Recommended Dose: 20 mg, 1 times / day Route: oral Route: multiple Dose: 20 mg, 1 times / day Sources: |
unhealthy n = 1145 Health Status: unhealthy Condition: Essential hypertension Population Size: 1145 Sources: |
Headache | 3% | 20 mg 1 times / day multiple, oral Recommended Dose: 20 mg, 1 times / day Route: oral Route: multiple Dose: 20 mg, 1 times / day Sources: |
unhealthy n = 1145 Health Status: unhealthy Condition: Essential hypertension Population Size: 1145 Sources: |
Cough increased | 1% | 40 mg 1 times / day multiple, oral Recommended Dose: 40 mg, 1 times / day Route: oral Route: multiple Dose: 40 mg, 1 times / day Sources: |
unhealthy n = 771 Health Status: unhealthy Condition: Essential hypertension Population Size: 771 Sources: |
Dizziness postural | 1% | 40 mg 1 times / day multiple, oral Recommended Dose: 40 mg, 1 times / day Route: oral Route: multiple Dose: 40 mg, 1 times / day Sources: |
unhealthy n = 771 Health Status: unhealthy Condition: Essential hypertension Population Size: 771 Sources: |
Nausea | 1% | 40 mg 1 times / day multiple, oral Recommended Dose: 40 mg, 1 times / day Route: oral Route: multiple Dose: 40 mg, 1 times / day Sources: |
unhealthy n = 771 Health Status: unhealthy Condition: Essential hypertension Population Size: 771 Sources: |
Dizziness | 2% | 40 mg 1 times / day multiple, oral Recommended Dose: 40 mg, 1 times / day Route: oral Route: multiple Dose: 40 mg, 1 times / day Sources: |
unhealthy n = 771 Health Status: unhealthy Condition: Essential hypertension Population Size: 771 Sources: |
Fatigue | 2% | 40 mg 1 times / day multiple, oral Recommended Dose: 40 mg, 1 times / day Route: oral Route: multiple Dose: 40 mg, 1 times / day Sources: |
unhealthy n = 771 Health Status: unhealthy Condition: Essential hypertension Population Size: 771 Sources: |
Headache | 3% | 40 mg 1 times / day multiple, oral Recommended Dose: 40 mg, 1 times / day Route: oral Route: multiple Dose: 40 mg, 1 times / day Sources: |
unhealthy n = 771 Health Status: unhealthy Condition: Essential hypertension Population Size: 771 Sources: |
Dizziness postural | 2% | 5 mg 1 times / day multiple, oral (max) Recommended Dose: 5 mg, 1 times / day Route: oral Route: multiple Dose: 5 mg, 1 times / day Sources: |
unhealthy n = 184 Health Status: unhealthy Condition: Essential hypertension Population Size: 184 Sources: |
Dizziness | 2% | 5 mg 1 times / day multiple, oral (max) Recommended Dose: 5 mg, 1 times / day Route: oral Route: multiple Dose: 5 mg, 1 times / day Sources: |
unhealthy n = 184 Health Status: unhealthy Condition: Essential hypertension Population Size: 184 Sources: |
Headache | 6% | 5 mg 1 times / day multiple, oral (max) Recommended Dose: 5 mg, 1 times / day Route: oral Route: multiple Dose: 5 mg, 1 times / day Sources: |
unhealthy n = 184 Health Status: unhealthy Condition: Essential hypertension Population Size: 184 Sources: |
Cough increased | 1% | 80 mg 1 times / day multiple, oral Recommended Dose: 80 mg, 1 times / day Route: oral Route: multiple Dose: 80 mg, 1 times / day Sources: |
unhealthy n = 86 Health Status: unhealthy Condition: Essential hypertension Population Size: 86 Sources: |
Nausea | 1% | 80 mg 1 times / day multiple, oral Recommended Dose: 80 mg, 1 times / day Route: oral Route: multiple Dose: 80 mg, 1 times / day Sources: |
unhealthy n = 86 Health Status: unhealthy Condition: Essential hypertension Population Size: 86 Sources: |
Headache | 2% | 80 mg 1 times / day multiple, oral Recommended Dose: 80 mg, 1 times / day Route: oral Route: multiple Dose: 80 mg, 1 times / day Sources: |
unhealthy n = 86 Health Status: unhealthy Condition: Essential hypertension Population Size: 86 Sources: |
Fatigue | 5% | 80 mg 1 times / day multiple, oral Recommended Dose: 80 mg, 1 times / day Route: oral Route: multiple Dose: 80 mg, 1 times / day Sources: |
unhealthy n = 86 Health Status: unhealthy Condition: Essential hypertension Population Size: 86 Sources: |
PubMed
Title | Date | PubMed |
---|---|---|
Sympathomoderating influence of benazepril in essential hypertension. | 1992 Apr |
|
Short-term metabolic effects of the ACE-inhibitor benazepril in type 2 diabetes mellitus associated with arterial hypertension. | 1992 Jul-Aug |
|
Antiatherogenic effect of angiotensin converting enzyme inhibitor (benazepril) and angiotensin II receptor antagonist (valsartan) in the cholesterol-fed rabbits. | 1999 Apr |
|
[The effects of blocking intrarenal renin-angiotensin system on the expression of transforming growth factor-beta1 mRNA and extracellular matrix components]. | 1999 Jan |
|
[Expression of type I transforming growth factor beta receptor in renal cortex in streptozotocin-induced diabetic rats and the regulation of benazepril]. | 1999 Jan |
|
Renal protective effects of blocking the intrarenal renin-angiotensin system. | 1999 Sep |
|
Safety of the combination of valsartan and benazepril in patients with chronic renal disease. European Group for the Investigation of Valsartan in Chronic Renal Disease. | 2000 Jan |
|
Effect of combination of valsartan with benazepril on blood pressure and left ventricular hypertrophy in SHR. | 2000 Nov |
|
ACE DD genotype is more susceptible than ACE II and ID genotypes to the antiproteinuric effect of ACE inhibitors in patients with proteinuric non-insulin-dependent diabetes mellitus. | 2000 Oct |
|
Renin-angiotensin system plays an important role in the regulation of water transport in the peritoneum. | 2001 |
|
Angiotensin-converting enzyme inhibition potentiates angiotensin II type 1 receptor effects on renal bradykinin and cGMP. | 2001 Aug |
|
Effects of the angiotensin converting enzyme inhibitor benazepril in cats with induced renal insufficiency. | 2001 Mar |
|
Combination of hydrochlorothiazide or benazepril with valsartan in hypertensive patients unresponsive to valsartan alone. | 2001 Nov |
|
Pilot study to evaluate a water displacement technique to compare effects of diuretics and ACE inhibitors to alleviate lower extremity edema due to dihydropyridine calcium antagonists. | 2001 Sep |
|
Effects of losartan and benazepril on abnormal circadian blood pressure rhythm and target organ damage in SHRSP. | 2002 Apr |
|
Effects of benazepril, an angiotensin-converting enzyme inhibitor, combined with CGS 35066, a selective endothelin-converting enzyme inhibitor, on arterial blood pressure in normotensive and spontaneously hypertensive rats. | 2002 Aug |
|
Using ACE inhibitors appropriately. | 2002 Aug 1 |
|
[The effects of angiotensin-converting enzyme inhibitor on IgA nephropathy and the influencing factors]. | 2002 Jun |
|
[Non-immunologic factor: immunosuppressive drug-induced nephrotoxicity]. | 2002 Nov |
|
The effects of antihypertensive agents on the survival rate of polycystic kidney disease in Han:SPRD rats. | 2002 Nov |
|
Effects of antihypertensive drugs on peritoneal vessels in hypertensive dogs with mild renal insufficiency. | 2003 |
|
ACE Inhibition with moexipril: a review of potential effects beyond blood pressure control. | 2003 |
|
Effect of benazepril amlodipine combination on fibrinolysis in hypertensive diabetic patients. | 2003 Aug |
|
Quantitative determination of benazepril and benazeprilat in human plasma by gas chromatography-mass spectrometry using automated 96-well disk plate solid-phase extraction for sample preparation. | 2003 Jan 5 |
|
Results of a pilot pharmacotherapy quality improvement program using fixed-dose, combination amlodipine/benazepril antihypertensive therapy in a long-term care setting. | 2003 Jun |
|
[Study on candidate genes of benazepril related cough in Chinese hypertensives]. | 2003 Jun |
|
Correlation of Angiotensin-converting enzyme gene polymorphism with effect of antihypertensive therapy by Angiotensin-converting enzyme inhibitor. | 2003 Mar |
|
Effects of combined ACE inhibitor and angiotensin II antagonist treatment in human chronic nephropathies. | 2003 Mar |
|
Adherence to antihypertensive therapy with fixed-dose amlodipine besylate/benazepril HCl versus comparable component-based therapy. | 2003 Nov-Dec |
|
[Vasopressin analogue injection as ultimate measure for counteracting severe catecholamine-refractory poisoning by several vasodilators taken with suicidal intent]. | 2003 Oct 17 |
|
Investigation of pimobendan versus benazepril in canine myxomatous valvular disease. | 2003 Oct 4 |
|
Systemic contact dermatitis due to captopril without cross-sensitivity to fosinopril, quinapril and benazepril. | 2004 |
|
Effects of co-administration of urokinase and benazepril on severe IgA nephropathy. | 2004 Apr |
|
Hypertensive patients from two rural Chinese counties respond differently to benazepril: the Anhui Hypertension Health Care Study. | 2004 Feb |
|
Effect of antihypertensive monotherapy and combination therapy on arterial distensibility and left ventricular mass. | 2004 Jan |
|
Stampidine prevents mortality in an experimental mouse model of viral hemorrhagic fever caused by lassa virus. | 2004 Jan 13 |
Patents
Sample Use Guides
The recommended initial dose for patients not receiving a diuretic is 10 mg once a day. The usual maintenance dosage range is 20-40 mg per day administered as a single dose or in two equally divided doses. A dose of 80 mg gives an increased response, but experience with this dose is limited.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/3140614
Benazepril inhibited both adrenaline-stimulated aortic PGI2 synthesis (25 pg mg -1 min-1) and carbachol-stimulated urinary bladder PGI2 synthesis (20 pg mg -1 min-1) in dose-dependent manners. IC50 (concentrations of antagonist at which agonist-stimulated PGI2 synthesis was inhibited by 50%) was 8 x 10-5.
Substance Class |
Chemical
Created
by
admin
on
Edited
Wed Jul 05 23:55:52 UTC 2023
by
admin
on
Wed Jul 05 23:55:52 UTC 2023
|
Record UNII |
UDM7Q7QWP8
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Brand Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NDF-RT |
N0000175562
Created by
admin on Wed Jul 05 23:55:52 UTC 2023 , Edited by admin on Wed Jul 05 23:55:52 UTC 2023
|
||
|
EMA VETERINARY ASSESSMENT REPORTS |
FORTEKOR PLUS [AUHTORIZED]
Created by
admin on Wed Jul 05 23:55:52 UTC 2023 , Edited by admin on Wed Jul 05 23:55:52 UTC 2023
|
||
|
NDF-RT |
N0000000181
Created by
admin on Wed Jul 05 23:55:52 UTC 2023 , Edited by admin on Wed Jul 05 23:55:52 UTC 2023
|
||
|
WHO-ATC |
C09AA07
Created by
admin on Wed Jul 05 23:55:52 UTC 2023 , Edited by admin on Wed Jul 05 23:55:52 UTC 2023
|
||
|
NCI_THESAURUS |
C247
Created by
admin on Wed Jul 05 23:55:52 UTC 2023 , Edited by admin on Wed Jul 05 23:55:52 UTC 2023
|
||
|
WHO-VATC |
QC09AA07
Created by
admin on Wed Jul 05 23:55:52 UTC 2023 , Edited by admin on Wed Jul 05 23:55:52 UTC 2023
|
||
|
WHO-ATC |
C09BA07
Created by
admin on Wed Jul 05 23:55:52 UTC 2023 , Edited by admin on Wed Jul 05 23:55:52 UTC 2023
|
||
|
WHO-VATC |
QC09BA07
Created by
admin on Wed Jul 05 23:55:52 UTC 2023 , Edited by admin on Wed Jul 05 23:55:52 UTC 2023
|
||
|
LIVERTOX |
NBK548659
Created by
admin on Wed Jul 05 23:55:52 UTC 2023 , Edited by admin on Wed Jul 05 23:55:52 UTC 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
6129
Created by
admin on Wed Jul 05 23:55:52 UTC 2023 , Edited by admin on Wed Jul 05 23:55:52 UTC 2023
|
PRIMARY | |||
|
BENAZEPRIL
Created by
admin on Wed Jul 05 23:55:52 UTC 2023 , Edited by admin on Wed Jul 05 23:55:52 UTC 2023
|
PRIMARY | |||
|
18867
Created by
admin on Wed Jul 05 23:55:52 UTC 2023 , Edited by admin on Wed Jul 05 23:55:52 UTC 2023
|
PRIMARY | RxNorm | ||
|
Benazepril
Created by
admin on Wed Jul 05 23:55:52 UTC 2023 , Edited by admin on Wed Jul 05 23:55:52 UTC 2023
|
PRIMARY | |||
|
C044946
Created by
admin on Wed Jul 05 23:55:52 UTC 2023 , Edited by admin on Wed Jul 05 23:55:52 UTC 2023
|
PRIMARY | |||
|
M2303
Created by
admin on Wed Jul 05 23:55:52 UTC 2023 , Edited by admin on Wed Jul 05 23:55:52 UTC 2023
|
PRIMARY | Merck Index | ||
|
SUB05700MIG
Created by
admin on Wed Jul 05 23:55:52 UTC 2023 , Edited by admin on Wed Jul 05 23:55:52 UTC 2023
|
PRIMARY | |||
|
100000090490
Created by
admin on Wed Jul 05 23:55:52 UTC 2023 , Edited by admin on Wed Jul 05 23:55:52 UTC 2023
|
PRIMARY | |||
|
DB00542
Created by
admin on Wed Jul 05 23:55:52 UTC 2023 , Edited by admin on Wed Jul 05 23:55:52 UTC 2023
|
PRIMARY | |||
|
5362124
Created by
admin on Wed Jul 05 23:55:52 UTC 2023 , Edited by admin on Wed Jul 05 23:55:52 UTC 2023
|
PRIMARY | |||
|
CHEMBL838
Created by
admin on Wed Jul 05 23:55:52 UTC 2023 , Edited by admin on Wed Jul 05 23:55:52 UTC 2023
|
PRIMARY | |||
|
6374
Created by
admin on Wed Jul 05 23:55:52 UTC 2023 , Edited by admin on Wed Jul 05 23:55:52 UTC 2023
|
PRIMARY | |||
|
3012
Created by
admin on Wed Jul 05 23:55:52 UTC 2023 , Edited by admin on Wed Jul 05 23:55:52 UTC 2023
|
PRIMARY | |||
|
DTXSID5022645
Created by
admin on Wed Jul 05 23:55:52 UTC 2023 , Edited by admin on Wed Jul 05 23:55:52 UTC 2023
|
PRIMARY | |||
|
UDM7Q7QWP8
Created by
admin on Wed Jul 05 23:55:52 UTC 2023 , Edited by admin on Wed Jul 05 23:55:52 UTC 2023
|
PRIMARY | |||
|
299
Created by
admin on Wed Jul 05 23:55:52 UTC 2023 , Edited by admin on Wed Jul 05 23:55:52 UTC 2023
|
PRIMARY | |||
|
3011
Created by
admin on Wed Jul 05 23:55:52 UTC 2023 , Edited by admin on Wed Jul 05 23:55:52 UTC 2023
|
PRIMARY | |||
|
86541-75-5
Created by
admin on Wed Jul 05 23:55:52 UTC 2023 , Edited by admin on Wed Jul 05 23:55:52 UTC 2023
|
PRIMARY | |||
|
C61645
Created by
admin on Wed Jul 05 23:55:52 UTC 2023 , Edited by admin on Wed Jul 05 23:55:52 UTC 2023
|
PRIMARY | |||
|
UDM7Q7QWP8
Created by
admin on Wed Jul 05 23:55:52 UTC 2023 , Edited by admin on Wed Jul 05 23:55:52 UTC 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
SALT/SOLVATE -> PARENT | |||
|
BINDER->LIGAND |
BINDING
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
METABOLITE ACTIVE -> PRODRUG |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> IMPURITY |
Impurity C: not more than 1.5 times the area of the principal peak in the chromatogram obtained with reference solution (c) (0.3 per cent)
|
Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
---|---|---|---|---|---|---|
Volume of Distribution | PHARMACOKINETIC |
|
|
|||
Biological Half-life | PHARMACOKINETIC |
|
|
|||